Therapeutic Advances for MED13L Syndrome: Drug Repurposing Studies to Combat Mitochondrial Dysfunction

Many caregivers for individuals with MED13L Syndrome report symptoms of tiring easily, low muscle tone, and overall lack of energy—this is exactly where understanding the health of the mitochondria in your kid’s cells is crucial! 

Since the MED13L gene is most prevalent in skeletal muscle and the Central Nervous System (CNS), it is even more important to focus on making sure mitochondria are in tip-top shape—they are the energy producers of the cell after all! 

Currently, Dr. Alicia Campbell has shown that mitochondrial dysfunction is present in all MED13L patient-derived samples (12 skin biopsies collected with Dr. Jen Bain @ Columbia), regardless of variant. Now, she is focusing on which FDA-approved drugs might help overcome this dysfunction at the cellular level, with the goal to eventually bring this to the patient population.  

Her current research is funded by a 1-year Post-Doctoral Fellowship through the MED13L Foundation, where she is testing various drugs for their efficacy in restoring cellular energy and function.

© 2025 The MED13L Foundation

|

Privacy Policy

|

Terms & Conditions

Site Search

Research & Family Meetup

Denver, Colorado, December 4th, 2026. This December, MED13L families will gather in person at the Grand Hyatt Denver. The day brings our community together around the latest MED13L research and the chance to spend real time with one another. Early bird pricing available!